Knocking down EBV-circLMP2A can inhibit the formation and migration of human umbilical vein endothelial cells (HUVEC), reduce the expression of VEGFA and HIF1α in cancer cells under hypoxia, and further promote angiogenesis [24]. The gene discussed is VEGFA; the disease is cancer.